Mapping the Mid-Year Shifts in Targeted Protein Degradation
Targeted protein degradation is building momentum, and 2025 is shaping up to be a landmark year. As of July, Beacon TPD tracks 2,346 assets, with 333 new drugs added in the first half alone – a 16% increase over H1 2024. Clinical activity is also surging, with 234 trial initiations on pace to set a new annual record.
While bivalent degraders continue to lead development, degrader–antibody conjugates (DACs) and molecular glues are showing the fastest growth. Meanwhile, investor focus is shifting, with $2.8B in disclosed deal value reflecting a more selective, data-driven funding environment.
This mid-year review provides unparalleled visibility into the evolving TPD landscape, covering drug and trial trends, emerging targets, deal activity, and regulatory updates that are defining the next phase of this modality.
The H1 2025 TPD Landscape Review
The Drug Landscape
Explore a pipeline that grew by 330+ TPD drugs in the first half of 2025, with bivalent degraders maintaining dominance and degrader–antibody conjugates (DACs) showing their fastest growth to date.
The Trial Landscape
Track 234 new clinical trials launched so far this year, on pace for a record-setting total, with alloimmune disorders, breast cancer, and lung cancer gaining notable momentum.
The Commercial Landscape
Uncover $2.8B in TPD-related deals at mid-year, as financing, M&A, and targeted licensing agreements shape a more selective investment environment.
Regulatory Announcement
Review recent approvals and global market expansions for therapies like inavolisib and omaveloxolone, signaling broader regulatory acceptance of TPD-based treatments.
The Future of TPD
Examine how novel effectors, from autophagic degradation to alternative E3 ligases, are expanding the reach of targeted protein degradation beyond traditional oncology.
Previous TPD Landscape Reviews
TPD 2024 H1 Landscape Review
An analysis of the TPD landscape in H1 of 2024
TPD 2024 Landscape Review
An analysis of the TPD landscape in 2024
You May Also Be Interested In…
Learn More About TPD
- The Most Comprehensive Way to Search the TPD Drug Development Landscape: Unique search ontologies based on TPD drug and trial characteristics
- Market Leading Approach to TPD Preclinical & Clinical Data Curation: Manual curation of key TPD research and development data points by TPD research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search TPD company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
